Device Trial Radar · NCT07949370
A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AML
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Mar 6, 2027
Primary completion
Dec 31, 2029
Study completion Jul 31, 2030
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AbbVie; National Cancer Institute (NCI); Stemline Therapeutics, Inc.; Syndax Pharmaceuticals
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the feasibility and efficacy of using the dynamic BH3 profiling (DBP) assay as a biomarker to guide venetoclax-based combination therapy for participants with relapsed or refractory acute myeloid leukemia (AML).
Conditions
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
Interventions
Dynamic BH3 ProfilingDevice
Dynamic BH3 Profiling is performed on myeloblasts obtained from a bone marrow aspirate to assess drug-induced apoptotic priming, using cytochrome c retention as the assay readout. The report evaluates venetoclax-based combinations and includes comparisons that are intra-patient and inter-patient (against a pooled historical dataset). The Protocol Tumor Board reviews the DBP report, screening findings, drug-specific eligibility, and patient and disease history to determine treatment assignment. The protocol defines feasibility as successful assay performance and delivery of the DBP report within five days of sample receipt.
VenetoclaxDrug
Venetoclax is a selective BCL-2 inhibitor administered as a component of every protocol treatment regimen. Target dose and duration are specific to each treatment regimen. Doses may be reduced when given with azoles or other interacting agents, and treatment may be held for clinically significant tumor lysis syndrome.
CytarabineDrug
Cytarabine will be tested in combination with venetoclax at different dosing strategies. Low-dose cytarabine will be combined with venetoclax in Arm 1. It is also administered as part of the venetoclax-cladribine-based regimen in Arm 6, at low or mid-intensity dosing based on age and fitness, and will be age-adjusted for safety.
GilteritinibDrug
Gilteritinib is administered in combination with venetoclax to participants assigned to Treatment 2 based on DBP findings and confirmation of regimen-specific eligibility.
Azacitidine (AZA)Drug
Azacitidine is administered with venetoclax and tagraxofusp in Arm 3 and with venetoclax and revumenib in Arm 5. Dosing of azacitidine is standard at 75 mg/m² daily on Days 1-7.
TagraxofuspDrug
Tagraxofusp is administered in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.
DecitabineDrug
Decitabine is administered in combination with venetoclax to participants assigned to Treatment 4 based on DBP findings and confirmation of regimen-specific eligibility.
RevumenibDrug
Revumenib is administered orally and in combination with venetoclax and azacitidine to participants assigned to Treatment 3 based on DBP findings and confirmation of regimen-specific eligibility.
Cladribine (CLAD)Drug
Cladribine is administered with venetoclax and low- or mid-intensity cytarabine in a combination regimen. ladribine is administered at 5 mg/m² daily on Days 1-5 of a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility Rate of Dynamic BH3 Profiling (DBP)Time frame: Within 5 days of receipt of a viable sample.
- Overall Response Rate (ORR)Time frame: Assessed at the end of Cycles 1, 2, and 4 (each cycle is 28 days), and every 3 cycles thereafter for up to 1 year, with an end-of-treatment assessment (up to 2 years; up to 3 months or 2 cycles for the cladribine/venetoclax arm).
- Reasons for Unsuccessful Assignment to DBP-Guided TherapyTime frame: During the screening period (up to 21 days).
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.